These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. 5-Lipoxygenase inhibitors: a review of recent developments and patents. Pergola C; Werz O Expert Opin Ther Pat; 2010 Mar; 20(3):355-75. PubMed ID: 20180620 [TBL] [Abstract][Full Text] [Related]
5. Recent advances in the search for novel 5-lipoxygenase inhibitors for the treatment of asthma. Bruno F; Spaziano G; Liparulo A; Roviezzo F; Nabavi SM; Sureda A; Filosa R; D'Agostino B Eur J Med Chem; 2018 Jun; 153():65-72. PubMed ID: 29133059 [TBL] [Abstract][Full Text] [Related]
6. Lipoxygenase Inhibitors as Cancer Chemopreventives: Discovery, Recent Developments and Future Perspectives. Mahboubi-Rabbani M; Zarghi A Curr Med Chem; 2021; 28(6):1143-1175. PubMed ID: 31820690 [TBL] [Abstract][Full Text] [Related]
7. Development of 5-lipoxygenase inhibitors--lessons from cellular enzyme regulation. Werz O; Steinhilber D Biochem Pharmacol; 2005 Aug; 70(3):327-33. PubMed ID: 15907806 [TBL] [Abstract][Full Text] [Related]
8. Further studies on ethyl 5-hydroxy-indole-3-carboxylate scaffold: design, synthesis and evaluation of 2-phenylthiomethyl-indole derivatives as efficient inhibitors of human 5-lipoxygenase. Peduto A; Bruno F; Dehm F; Krauth V; de Caprariis P; Weinigel C; Barz D; Massa A; De Rosa M; Werz O; Filosa R Eur J Med Chem; 2014 Jun; 81():492-8. PubMed ID: 24871899 [TBL] [Abstract][Full Text] [Related]
10. An experimental cell-based model for studying the cell biology and molecular pharmacology of 5-lipoxygenase-activating protein in leukotriene biosynthesis. Gerstmeier J; Weinigel C; Barz D; Werz O; Garscha U Biochim Biophys Acta; 2014 Sep; 1840(9):2961-9. PubMed ID: 24905297 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of 5-lipoxygenase product synthesis by natural compounds of plant origin. Werz O Planta Med; 2007 Oct; 73(13):1331-57. PubMed ID: 17939102 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological cross-reactivity between 5-lipoxygenase-activating protein, 5-lipoxygenase, and leukotriene C4 synthase. Gupta N; Nicholson DW; Ford-Hutchinson AW Can J Physiol Pharmacol; 1997; 75(10-11):1212-9. PubMed ID: 9431445 [TBL] [Abstract][Full Text] [Related]
14. Structural insight into the optimization of ethyl 5-hydroxybenzo[g]indol-3-carboxylates and their bioisosteric analogues as 5-LO/m-PGES-1 dual inhibitors able to suppress inflammation. Bruno F; Errico S; Pace S; Nawrozkij MB; Mkrtchyan AS; Guida F; Maisto R; Olgaç A; D'Amico M; Maione S; De Rosa M; Banoglu E; Werz O; Fiorentino A; Filosa R Eur J Med Chem; 2018 Jul; 155():946-960. PubMed ID: 30015253 [TBL] [Abstract][Full Text] [Related]
15. 5-Lipoxygenase as a drug target: A review on trends in inhibitors structural design, SAR and mechanism based approach. Sinha S; Doble M; Manju SL Bioorg Med Chem; 2019 Sep; 27(17):3745-3759. PubMed ID: 31331653 [TBL] [Abstract][Full Text] [Related]
16. Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610. Fischer L; Steinhilber D; Werz O Br J Pharmacol; 2004 Jul; 142(5):861-8. PubMed ID: 15197110 [TBL] [Abstract][Full Text] [Related]
17. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Evans JF; Ferguson AD; Mosley RT; Hutchinson JH Trends Pharmacol Sci; 2008 Feb; 29(2):72-8. PubMed ID: 18187210 [TBL] [Abstract][Full Text] [Related]
18. Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma. Drazen JM Pharmacotherapy; 1997; 17(1 Pt 2):22S-30S. PubMed ID: 9017785 [TBL] [Abstract][Full Text] [Related]
19. Characterization of the interaction of human 5-lipoxygenase with its activating protein FLAP. Häfner AK; Gerstmeier J; Hörnig M; George S; Ball AK; Schröder M; Garscha U; Werz O; Steinhilber D Biochim Biophys Acta; 2015 Nov; 1851(11):1465-72. PubMed ID: 26327594 [TBL] [Abstract][Full Text] [Related]